Clinical Trial Update: Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CART2219.1, a dual anti-CD22/CD19 CAR-T therapy, in relapsed/refractory B-lineage leukemia, spanning Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Leukemia
• Lymphoblastic Leukemia Acute
• Lymphoblastic Leukemia Acute Adult
• Lymphoblastic Leukemia in Children

Drugs mentioned

• CART2219.1 (CART2219.1)

Snippet

Sponsor: KK Women's and Children's Hospital | Conditions: Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood | Phase 1, Phase 2 | Status: UNKNOWN